INSP250117C155000
- 52.72
- 0.000.00%
Inspire Medical Systems Newsroom
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $198
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $198
Inspire Medical Systems: Balancing Growth Prospects and Market Challenges – A Hold Rating by Larry Biegelsen
Leerink Partners Sticks to Their Hold Rating for Inspire Medical Systems (INSP)
Inspire Medical Systems Analyst Ratings
BofA Securities Upgrades Inspire Medical Systems(INSP.US) to Buy Rating, Raises Target Price to $255
Inspire Medical Systems Maintains Strong Market Position Amidst LIVN's Aura6000 Uncertainties
Lake Street Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $270
A Quick Look at Today's Ratings for Inspire Medical Systems(INSP.US), With a Forecast Between $200 to $270
Inspire Medical Systems: Mixed Signals Lead to Hold Rating Amid Utilization and Competitive Challenges
Inspire Medical Systems Price Target Raised to $198.00/Share From $187.00 by Wells Fargo
A Quick Look at Today's Ratings for Inspire Medical Systems(INSP.US), With a Forecast Between $198 to $260
Inspire Medical Systems Is Maintained at Outperform by Baird
Inspire Medical Systems Analyst Ratings
KeyBanc Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
Baird Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Raises Target Price to $240
Mizuho Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Cuts Target Price to $230
RBC Capital Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
RBC Capital Sticks to Their Buy Rating for Inspire Medical Systems (INSP)